OMR15mn factory opens in Raysut Industrial City

Oman Wednesday 18/September/2024 20:37 PM
By: ONA
OMR15mn factory opens in Raysut Industrial City

Salalah: In a major stride towards strengthening Oman’s healthcare sector, the Dhofar Pharmaceutical Industries Factory was inaugurated on Wednesday at Raysut Industrial City in Salalah.

With an investment exceeding OMR15million, the cutting-edge facility aims to boost the nation’s drug security and reduce reliance on imports by manufacturing intravenous and kidney dialysis solutions locally.

The opening ceremony was presided over by Qais bin Mohammed Al Yousef, Minister of Commerce, Industry, and Investment Promotion, alongside Dr. Hilal bin Ali Al Sabti, Minister of Health, and other distinguished officials.

Built over an expansive 22,000-square-metre area, the factory is equipped with advanced German technologies and adheres to the highest international standards.The project is set to play a critical role in meeting both local and regional demand for pharmaceutical solutions, bolstering Oman’s health security and its goal of reducing reliance on imports.

“This factory is a product of the Health Sector Investment Lab, launched by the Ministry of Health in 2022, in collaboration with Nazdar and aligned with Oman Vision 2040,” said Al Yousef.

He emphasised that the factory is a key addition to the industrial expansion in Dhofar Governorate, underlining its role in supporting Oman’s strategic objectives in health and industry.

With an annual production capacity of 15million units of intravenous solutions and 2.3 million units of kidney dialysis solutions, the factory will easily meet the estimated demand of 5 million units annually within Oman’s health sector.

Sheikh Salem bin Ali Amer Jaid Al Mahri, Chairman of Dhofar Pharmaceutical Industries, highlighted the company’s focus on accommodating national talent and expertise to ensure high-quality production.

Dr. Mohammed bin Hamdan Al-Rubaie, Director General of the Drug Safety Centre at the Ministry of Health, pointed out that the facility complies with both the US FDA and European Medicines Agency standards, further cementing its role as a strategic project that enhances Oman’s self-sufficiency in essential medical supplies.

The factory is set to not only stabilise local prices but also reduce the country’s dependency on volatile international markets, reinforcing Oman’s position in the global pharmaceutical industry while advancing research and innovation in the sector.

This project marks a significant step toward building a more resilient and sustainable health system, ensuring Oman is better equipped to respond to emergencies and improve patient care.